Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Taxes: 2022-2025

Historic Current Taxes for Gyre Therapeutics (GYRE) over the last 2 years, with Sep 2025 value amounting to $2.6 million.

  • Gyre Therapeutics' Current Taxes fell 6.90% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 6.90%. This contributed to the annual value of $2.8 million for FY2024, which is 43.98% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Current Taxes stood at $2.6 million, which was up 144.10% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Current Taxes registered a high of $6.5 million during Q1 2024, and its lowest value of $569,000 during Q1 2025.
  • Moreover, its 3-year median value for Current Taxes was $2.7 million (2024), whereas its average is $3.0 million.
  • Per our database at Business Quant, Gyre Therapeutics' Current Taxes surged by 140.55% in 2023 and then tumbled by 91.21% in 2025.
  • Over the past 4 years, Gyre Therapeutics' Current Taxes (Quarterly) stood at $2.1 million in 2022, then spiked by 140.55% to $5.1 million in 2023, then crashed by 43.98% to $2.8 million in 2024, then declined by 6.90% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $1.1 million for Q2 2025, and $569,000 during Q1 2025.